Exact Sciences Announced Presentation of New Data at San Antonio Breast Cancer Symposium Supporting Clinical Value of the Oncotype DX Breast Recurrence Score Test
Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium® (SABCS®) supporting the clinical value of the Oncotype DX Breast Recurrence Score test.
Exact Sciences Highlights Publication Of New England Journal Of Medicine Confirms Women With Node-Positive, Early-Stage Breast Cancer Can Avoid Chemo With Oncotype DX Test
- RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women
- Results have already led
Exact Sciences And Pfizer Enter Amendment To Amended & Restated Cologuard Promotion Agreement; Exact To Pay Pfizer $35,900,000 In Three Installments During Q2, Q3 And Q4 Of 2022
On November 29, 2021, Exact Sciences Corporation (the “Company”) and Pfizer Inc. (“Pfizer”) entered into an amendment (the “Amendment”) to the Amended & Restated
Exact Sciences Highlights New 20-Year Data Published In ‘Urologic Oncology’ Validates Adverse Pathology As Predictor Of Prostate Cancer Outcomes In Low-Risk Patients
Exact Sciences Corp. (NASDAQ:EXAS), a global leader in cancer diagnostics, today announced the publication of results underscoring the importance of adverse pathology as a reliable and critical endpoint for
Cathie Wood’s ARK Invest Posts Fund Purchases For Monday, Nov. 8, 2021: ZM, EXAS, ADPT, PACB, HOOD
Zoom Video Communications (ZM)
Exact Sciences (EXAS)
Adaptive Biotechnologies (ADPT)
Pacific Biosciences of California (PACB)
Robinhood Markets (HOOD)
Cathie Wood’s ARK Invest Posts Fund Purchases For Wednesday, Nov. 3, 2021
Zoom Video (ZM)
Exact Sciences (EXAS)
Twilio (TWLO)
Robinhood (HOOD)
UIPath (PATH)
DraftKings (DKNG)
Intellia Therapeutics (NTLA)
Beam Therapeutics (BEAM)
Teladoc (TDOC)
NIU Technologies
54 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
iRhythm Technologies, Inc. (NASDAQ: IRTC) climbed 38.9% to $106.64. iRhythm Technologies commented on the Centers for Medicare and Medicaid Services (CMS) Calendar Year 2022 Medicare Physician Fee Schedule (MPFS) Final Rule.
Exact Sciences Shares Drop After Guiding Lower Screening Revenue For FY21
Exact Sciences Corp’s (NASDAQ:EXAS) Q3 revenues rose 12% Y/Y to $456.4 million, beating the consensus of $430.03 million. The increase…